Baird Downgrades Nivalis Therapeutics (NVLS) to Neutral Following Clinical Failure

November 29, 2016 6:14 AM EST
Get Alerts NVLS Hot Sheet
Price: $2.14 +1.42%

Rating Summary:
    1 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade NVLS Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Baird downgraded Nivalis Therapeutics (NASDAQ: NVLS) from Outperform to Neutral with a price target of $3.00 (from $29.00) after clinical trial failure.

Analyst Brian Skorney commented, "Nivalis announced that the company's flagship proof-of-concept study of cavosonstat in combination with Vertex's Orkambi failed to show an improvement in lung function. Although a second study is still ongoing, we believe the absence of any clinical effect indicates that cavosonstat isn't a relevant drug for cystic fibrosis. At this point, we are assuming that the company will wind down operations after completing the ongoing Kalydeco combination study. We are lowering our price target to $3."

For an analyst ratings summary and ratings history on Nivalis Therapeutics click here. For more ratings news on Nivalis Therapeutics click here.

Shares of Nivalis Therapeutics closed at $6.25 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

Robert W Baird

Add Your Comment